COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society

A working group convened by the Section of Multiple Sclerosis and Neuroimmunology Polish Neurological Society has developed a statement with regard to currently available mRNA vaccines (Pfizer-BioNTech Moderna) preventing novel coronavirus (severe acute respiratory syndrome 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients multiple sclerosis (MS). This been based on literature as 15 January, 2021. The guidance will be updated new data emerges. All regarding above-mentioned comes from clinical trials have reviewed, published approved regulatory authorities [1, 2]. In current manuscript, whenever SARS-CoV-2 vaccine is discussed, it refers only.